Treatment preferences of originator versus biosimilar drugs in Crohns disease; Discrete choice experiment among gastroenterologists

Scandinavian Journal of Gastroenterology

Volumn 51, Issue 1, 2016, Pages 22-27

  Baji, Petra ^a,b   Gulácsi, László ^a   Lovász, Barbara D ^c   Golovics, Petra A ^c   Brodszky, Valentin ^a   Péntek, Márta ^a,d   Rencz, Fanni ^a,e   Lakatos, Péter L ^c  

^a Institute of Data Analytics and Information Systems   (Hungary)

^b CERGE EI   (Czech Republic)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d Pest Megyei Flor Ferenc Korhaz   (Hungary)

^e SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Biologicals; biosimilars; Crohn's disease; discrete choice experiment; preference

Indexed keywords

BIOSIMILAR AGENT; CT-P13; INFLIXIMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CONSULTATION; CROHN DISEASE; DISEASE SEVERITY; DRUG CHOICE; DRUG PREFERENCE; FEMALE; GASTROENTEROLOGIST; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; REIMBURSEMENT; ATTITUDE TO HEALTH; CLINICAL PRACTICE; DECISION MAKING; ECONOMICS; HUNGARY; MIDDLE AGED; PHYSICIAN; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; CHOICE BEHAVIOR; CROHN DISEASE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HUNGARY; INFLIXIMAB; MALE; MIDDLE AGED; PHYSICIANS; PRACTICE PATTERNS, PHYSICIANS'; SURVEYS AND QUESTIONNAIRES;

EID: 84944931026     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2015.1054422     Document Type: Article

References (18)

1. Baji P, Péntek M, Czirják L, Szekanecz Z, Nagy G, et al. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur J Health Econ 2014; 15: S53-64.
2. Baji P, Péntek M, Szántó S, Géher P, Gulácsi L, Balogh O, et al. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. Eur J Health Econ 2014; 15: S45-52.
3. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72: 1613-20.
4. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72: 1605-12.
5. Gecse K, Farkas K, Lovasz B, Banai J, Bene L, Gasztonyi B, et al. Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort. J Crohns Colitis 2015; 9: S234-5.
6. Tóthfalusi L, Endrényi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ 2014; 15: S5-11.
7. Rencz F, Péntek M, Bortlik M, Zagorowicz E, Hlavaty T, ͆liwczyński A, et al. Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. World J Gastroenterol 2015; 21: 1728-37.
8. Brodszky V, Baji P, Balogh O, Péntek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014; 15: S65-71.
9. Danese S, Fiorino G, Michetti P. Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohns and Colitis Organization. J Crohns Colitis 2014; 8: 1548-50.
10. Grabowski D, Henderson B, Lam D, Keystone EC, Thorne C, Jamal S, et al. Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists. Clin Rheumatol 2015; Epub ahead of print.
11. de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ 2012; 21: 145-72.
12. Hanley N, Ryan M, Wright R. Estimating the monetary value of health care: lessons from environmental economics. Health Econ 2003; 12: 3-16.
13. Johnson FR, Hauber B, Özdemir S, Siegel CA, Hass S, Sands BE. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohns disease management. J Manag Care Pharm 2010; 16: 616-28.
14. Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, et al. Crohns disease patients risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007; 133: 769-79.
15. Lichtenstein GR, Waters HC, Kelly J, McDonald SS, Zanutto EL, Hendricks D, et al. Assessing drug treatment preferences of patients with Crohns disease a conjoint analysis. Patient 2010; 3: 113-23.
16. Freeman HJ. Use of the Crohns disease activity index in clinical trials of biological agents. World J Gastroenterol 2008; 14: 4127-30.
17. Campbell EG, Pham-Kanter G, Vogeli C, Iezzoni LI. Physician acquiescence to patient demands for brand-name drugs: results of a national survey of physicians. JAMA Intern Med 2013; 173: 237-9.
18. Dunne S, Shannon B, Hannigan A, Dunne C, Cullen W. Physician and pharmacist perceptions of generic medicines: what they think and how they differ. Health Policy 2014; 116: 214-23.